Board of Directors

Hoyoung Huh, M.D., Ph.D., is chairman of the board of directors for Pliant. Dr. Huh currently serves as Chairman of the Board of Akari Therapeutics, a public targeted oncology company following its November 2024 merger with Peak Bio (formerly known as pH Pharma). Dr. Huh founded Peak Bio where he served as its Chief Executive Officer and Chairman of the Board. Dr. Huh previously served as chairman to the board of directors for Geron Corporation, CytomX Therapeutics and Epizyme, Inc. He was also a director of Eidos Therapeutics, Rezolute, Facet Biotech, Nektar Therapeutics, Addex Therapeutics and EOS, S.p.A (Milano, Italy). Earlier in his career, Dr. Huh was a partner at McKinsey & Company.

He holds a B.A. in biochemistry from Dartmouth College, an M.D. from Cornell University Medical College, and a Ph.D. in cell biology and genetics from Cornell University/Sloan-Kettering Institute.